Barcha huquqlar himoyalangan.
7.80
0.00 (0.00%)
Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026
Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS)
EMERYVILLE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced that company management will participate in the following upcoming conferences: Leerink Partners 2026 Global Healthcare Conference Format: Fireside chat and investor meetingsDate: Monday, March 9th, 2026Time: 11:20 a.m.
Kyverna Therapeutics leads CAR-T therapy for autoimmune diseases, with KYV-101 showing unprecedented efficacy in SPS and MG registrational trials. KYTX's SPS trial achieved 81% clinically meaningful improvement and all secondary endpoints, positioning the company for a BLA filing in 1H 2026. With a $279M cash runway into 2028 and strong institutional backing, KYTX is de-risked from near-term dilution and aligns with top-tier biotech investors.
Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.
There is no data to display
